Cytokinetics, Incorporated (CYTK)
USD 37.12
(-8.39%)
USD 37.12
(-8.39%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 824.31 Million USD | -18.77% |
| 2022 | 1.01 Billion USD | 20.62% |
| 2021 | 841.31 Million USD | 57.61% |
| 2020 | 533.8 Million USD | 84.19% |
| 2019 | 289.81 Million USD | 37.24% |
| 2018 | 211.17 Million USD | -28.37% |
| 2017 | 294.81 Million USD | 73.27% |
| 2016 | 170.14 Million USD | 47.65% |
| 2015 | 115.23 Million USD | -13.33% |
| 2014 | 132.96 Million USD | 59.84% |
| 2013 | 83.18 Million USD | 7.27% |
| 2012 | 77.55 Million USD | 46.95% |
| 2011 | 52.77 Million USD | -32.34% |
| 2010 | 77.99 Million USD | -36.38% |
| 2009 | 122.59 Million USD | 40.19% |
| 2008 | 87.45 Million USD | -43.71% |
| 2007 | 155.37 Million USD | -8.34% |
| 2006 | 169.51 Million USD | 85.34% |
| 2005 | 91.46 Million USD | -28.6% |
| 2004 | 128.1 Million USD | 103.75% |
| 2003 | 62.87 Million USD | 11.94% |
| 2002 | 56.16 Million USD | -28.92% |
| 2001 | 79.01 Million USD | 29.46% |
| 2000 | 61.03 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 808.08 Million USD | -1.97% |
| 2024 Q2 | 1.52 Billion USD | 88.57% |
| 2023 Q3 | 740.61 Million USD | -5.04% |
| 2023 Q4 | 824.31 Million USD | 11.3% |
| 2023 FY | 824.31 Million USD | -18.77% |
| 2023 Q1 | 889.81 Million USD | -12.31% |
| 2023 Q2 | 779.89 Million USD | -12.35% |
| 2022 Q3 | 1.07 Billion USD | 39.42% |
| 2022 Q2 | 771.71 Million USD | -9.87% |
| 2022 Q1 | 856.25 Million USD | 1.78% |
| 2022 FY | 1.01 Billion USD | 20.62% |
| 2022 Q4 | 1.01 Billion USD | -5.69% |
| 2021 Q3 | 827.53 Million USD | 46.65% |
| 2021 FY | 841.31 Million USD | 57.61% |
| 2021 Q1 | 577.06 Million USD | 8.1% |
| 2021 Q2 | 564.3 Million USD | -2.21% |
| 2021 Q4 | 841.31 Million USD | 1.67% |
| 2020 Q1 | 256.58 Million USD | -11.47% |
| 2020 FY | 533.8 Million USD | 84.19% |
| 2020 Q4 | 533.8 Million USD | 12.59% |
| 2020 Q3 | 474.11 Million USD | 103.92% |
| 2020 Q2 | 232.49 Million USD | -9.39% |
| 2019 Q1 | 198.61 Million USD | -5.95% |
| 2019 Q3 | 187.39 Million USD | -5.46% |
| 2019 Q4 | 289.81 Million USD | 54.66% |
| 2019 FY | 289.81 Million USD | 37.24% |
| 2019 Q2 | 198.21 Million USD | -0.2% |
| 2018 FY | 211.17 Million USD | -28.37% |
| 2018 Q1 | 279.92 Million USD | -5.05% |
| 2018 Q3 | 230.27 Million USD | -6.86% |
| 2018 Q2 | 247.23 Million USD | -11.68% |
| 2018 Q4 | 211.17 Million USD | -8.29% |
| 2017 Q4 | 294.81 Million USD | -9.65% |
| 2017 FY | 294.81 Million USD | 73.27% |
| 2017 Q1 | 265.37 Million USD | 55.97% |
| 2017 Q2 | 340.63 Million USD | 28.36% |
| 2017 Q3 | 326.31 Million USD | -4.2% |
| 2016 Q1 | 113.21 Million USD | -1.75% |
| 2016 FY | 170.14 Million USD | 47.65% |
| 2016 Q4 | 170.14 Million USD | 7.57% |
| 2016 Q2 | 106.16 Million USD | -6.23% |
| 2016 Q3 | 158.17 Million USD | 48.99% |
| 2015 Q2 | 112.7 Million USD | -7.78% |
| 2015 Q3 | 102.19 Million USD | -9.33% |
| 2015 Q4 | 115.23 Million USD | 12.76% |
| 2015 FY | 115.23 Million USD | -13.33% |
| 2015 Q1 | 122.21 Million USD | -8.09% |
| 2014 Q3 | 87.18 Million USD | -9.32% |
| 2014 Q4 | 132.96 Million USD | 52.51% |
| 2014 FY | 132.96 Million USD | 59.84% |
| 2014 Q1 | 107.27 Million USD | 28.96% |
| 2014 Q2 | 96.14 Million USD | -10.38% |
| 2013 Q1 | 64.69 Million USD | -16.58% |
| 2013 Q3 | 88 Million USD | -6.93% |
| 2013 Q4 | 83.18 Million USD | -5.47% |
| 2013 FY | 83.18 Million USD | 7.27% |
| 2013 Q2 | 94.55 Million USD | 46.17% |
| 2012 Q2 | 94.08 Million USD | 102.19% |
| 2012 FY | 77.55 Million USD | 46.95% |
| 2012 Q4 | 77.55 Million USD | -9.13% |
| 2012 Q1 | 46.53 Million USD | -11.83% |
| 2012 Q3 | 85.34 Million USD | -9.29% |
| 2011 Q4 | 52.77 Million USD | -14.58% |
| 2011 FY | 52.77 Million USD | -32.34% |
| 2011 Q2 | 72.15 Million USD | 9.89% |
| 2011 Q1 | 65.66 Million USD | -15.81% |
| 2011 Q3 | 61.77 Million USD | -14.38% |
| 2010 Q1 | 111.89 Million USD | -8.73% |
| 2010 Q4 | 77.99 Million USD | -5.94% |
| 2010 FY | 77.99 Million USD | -36.38% |
| 2010 Q3 | 82.91 Million USD | -12.36% |
| 2010 Q2 | 94.61 Million USD | -15.44% |
| 2009 Q4 | 122.59 Million USD | -8.62% |
| 2009 FY | 122.59 Million USD | 40.19% |
| 2009 Q1 | 92.92 Million USD | 6.25% |
| 2009 Q3 | 134.16 Million USD | -6.88% |
| 2009 Q2 | 144.06 Million USD | 55.04% |
| 2008 Q2 | 119.36 Million USD | -13.71% |
| 2008 FY | 87.45 Million USD | -43.71% |
| 2008 Q1 | 138.33 Million USD | -10.96% |
| 2008 Q4 | 87.45 Million USD | -12.58% |
| 2008 Q3 | 100.04 Million USD | -16.19% |
| 2007 Q2 | 172.81 Million USD | -7.58% |
| 2007 Q3 | 168.7 Million USD | -2.38% |
| 2007 FY | 155.37 Million USD | -8.34% |
| 2007 Q1 | 186.99 Million USD | 10.31% |
| 2007 Q4 | 155.37 Million USD | -7.9% |
| 2006 Q3 | 104.64 Million USD | -4.5% |
| 2006 Q1 | 114.66 Million USD | 25.37% |
| 2006 FY | 169.51 Million USD | 85.34% |
| 2006 Q4 | 169.51 Million USD | 61.99% |
| 2006 Q2 | 109.57 Million USD | -4.44% |
| 2005 Q2 | 105.2 Million USD | -10.72% |
| 2005 Q3 | 95.9 Million USD | -8.84% |
| 2005 Q4 | 91.46 Million USD | -4.63% |
| 2005 FY | 91.46 Million USD | -28.6% |
| 2005 Q1 | 117.83 Million USD | -8.02% |
| 2004 Q3 | 138.92 Million USD | -7.07% |
| 2004 Q4 | 128.1 Million USD | -7.79% |
| 2004 FY | 128.1 Million USD | 103.75% |
| 2004 Q2 | 149.5 Million USD | 166.17% |
| 2004 Q1 | 56.16 Million USD | -10.66% |
| 2003 Q4 | 62.87 Million USD | 0.0% |
| 2003 FY | 62.87 Million USD | 11.94% |
| 2002 FY | 56.16 Million USD | -28.92% |
| 2001 FY | 79.01 Million USD | 29.46% |
| 2000 FY | 61.03 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AbCellera Biologics Inc. | 1.48 Billion USD | 44.606% |
| Alkermes plc | 2.13 Billion USD | 61.412% |
| Agenus Inc. | 313.91 Million USD | -162.594% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 78.477% |
| Aptorum Group Limited | 20.64 Million USD | -3893.761% |
| Ardelyx, Inc. | 297.57 Million USD | -177.007% |
| Arrowhead Pharmaceuticals, Inc. | 765.55 Million USD | -7.676% |
| Bicycle Therapeutics plc | 595.34 Million USD | -38.46% |
| BioXcel Therapeutics, Inc. | 73.7 Million USD | -1018.445% |
| ChromaDex Corporation | 54.96 Million USD | -1399.738% |
| Chimerix, Inc. | 212.77 Million USD | -287.414% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -2815.622% |
| Caribou Biosciences, Inc. | 440.96 Million USD | -86.933% |
| CRISPR Therapeutics AG | 2.22 Billion USD | 63.028% |
| Precision BioSciences, Inc. | 159.78 Million USD | -415.904% |
| Dyadic International, Inc. | 8.21 Million USD | -9929.107% |
| Eton Pharmaceuticals, Inc. | 31.74 Million USD | -2497.089% |
| Fortress Biotech, Inc. | 167.52 Million USD | -392.053% |
| Lantern Pharma Inc. | 43.64 Million USD | -1788.571% |
| HOOKIPA Pharma Inc. | 161.33 Million USD | -410.928% |
| Inhibikase Therapeutics, Inc. | 14.5 Million USD | -5582.333% |
| Incyte Corporation | 6.78 Billion USD | 87.846% |
| IO Biotech, Inc. | 150.71 Million USD | -446.926% |
| Jaguar Health, Inc. | 50.76 Million USD | -1523.852% |
| Novavax, Inc. | 1.85 Billion USD | 55.571% |
| Janux Therapeutics, Inc. | 380.4 Million USD | -116.693% |
| Opthea Limited | 188.79 Million USD | -336.628% |
| Ligand Pharmaceuticals Incorporated | 833.06 Million USD | 1.05% |
| ContextLogic Inc. | 423 Million USD | -94.874% |
| MiMedx Group, Inc. | 239.04 Million USD | -244.834% |
| Pyxis Oncology, Inc. | 173.72 Million USD | -374.492% |
| TransCode Therapeutics, Inc. | 5.16 Million USD | -15845.139% |
| NextCure, Inc. | 129.41 Million USD | -536.941% |
| Ocuphire Pharma, Inc. | 53.94 Million USD | -1427.983% |
| Oncternal Therapeutics, Inc. | 36.72 Million USD | -2144.319% |
| Outlook Therapeutics, Inc. | 32.3 Million USD | -2451.983% |
| Vaxcyte, Inc. | 1.4 Billion USD | 41.451% |
| PDS Biotechnology Corporation | 59.39 Million USD | -1287.969% |
| Madrigal Pharmaceuticals, Inc. | 640.54 Million USD | -28.689% |
| Pharming Group N.V. | 462.85 Million USD | -78.094% |
| Pieris Pharmaceuticals, Inc. | 38.68 Million USD | -2031.117% |
| Avidity Biosciences, Inc. | 628.55 Million USD | -31.145% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -4256.004% |
| Reviva Pharmaceuticals Holdings, Inc. | 18.92 Million USD | -4256.004% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -398.618% |
| Sol-Gel Technologies Ltd. | 45.28 Million USD | -1720.204% |
| Acelyrin, Inc. | 742.69 Million USD | -10.991% |
| Salarius Pharmaceuticals, Inc. | 6.58 Million USD | -12415.192% |
| SELLAS Life Sciences Group, Inc. | 6.4 Million USD | -12773.903% |
| Summit Therapeutics Inc. | 202.94 Million USD | -306.169% |
| Sensei Biotherapeutics, Inc. | 74.37 Million USD | -1008.339% |
| Senti Biosciences, Inc. | 119.48 Million USD | -589.897% |
| Stoke Therapeutics, Inc. | 228.34 Million USD | -261.001% |
| Syros Pharmaceuticals, Inc. | 168.17 Million USD | -390.157% |
| Alaunos Therapeutics, Inc. | 8.26 Million USD | -9875.989% |
| Telomir Pharmaceuticals, Inc. Common Stock | 4.77 Million USD | -17167.618% |
| Entrada Therapeutics, Inc. | 469.19 Million USD | -75.688% |
| VistaGen Therapeutics, Inc. | 123.65 Million USD | -566.636% |
| Wave Life Sciences Ltd. | 274.94 Million USD | -199.807% |
| Sorrento Therapeutics, Inc. | 472.84 Million USD | -74.333% |
| TRACON Pharmaceuticals, Inc. | 10.1 Million USD | -8057.506% |
| Barinthus Biotherapeutics plc | 214.5 Million USD | -284.286% |
| Psyence Biomedical Ltd. | 1.13 Million USD | -72709.208% |
| Phathom Pharmaceuticals, Inc. | 413.84 Million USD | -99.186% |
| Immix Biopharma, Inc. | 19.92 Million USD | -4037.061% |
| Keros Therapeutics, Inc. | 370.02 Million USD | -122.773% |
| MEI Pharma, Inc. | 41.37 Million USD | -1892.305% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -2443.714% |
| Xeris Biopharma Holdings, Inc. | 340.79 Million USD | -141.878% |
| Rigel Pharmaceuticals, Inc. | 117.22 Million USD | -603.191% |
| Fortress Biotech, Inc. | 167.52 Million USD | -392.053% |
| Precigen, Inc. | 151.04 Million USD | -445.749% |
| Clearside Biomedical, Inc. | 34.01 Million USD | -2323.176% |
| AlloVir, Inc. | 190.79 Million USD | -332.041% |
| C4 Therapeutics, Inc. | 376.45 Million USD | -118.97% |
| Fate Therapeutics, Inc. | 506.21 Million USD | -62.838% |
| ImmuCell Corporation | 43.8 Million USD | -1781.652% |
| IDEAYA Biosciences, Inc. | 649.31 Million USD | -26.951% |
| Onconetix, Inc. | 88.82 Million USD | -828.06% |
| PureTech Health plc | 693.97 Million USD | -18.782% |
| VYNE Therapeutics Inc. | 97.68 Million USD | -743.851% |
| Elevation Oncology, Inc. | 89.09 Million USD | -825.252% |
| Kintara Therapeutics, Inc. | 6.2 Million USD | -13191.132% |
| Seer, Inc. | 436.26 Million USD | -88.947% |
| Verrica Pharmaceuticals Inc. | 81.59 Million USD | -910.228% |
| Innoviva, Inc. | 1.24 Billion USD | 33.71% |
| Aadi Bioscience, Inc. | 132.42 Million USD | -522.487% |
| ESSA Pharma Inc. | 149.12 Million USD | -452.779% |
| GlycoMimetics, Inc. | 45.31 Million USD | -1719.021% |
| GT Biopharma, Inc. | 14.1 Million USD | -5742.484% |
| Inhibrx Biosciences, Inc. | 307.89 Million USD | -167.728% |
| Akebia Therapeutics, Inc. | 241.7 Million USD | -241.045% |
| Catalyst Pharmaceuticals, Inc. | 471.9 Million USD | -74.678% |
| Longboard Pharmaceuticals, Inc. | 50.69 Million USD | -1525.966% |
| Orchestra BioMed Holdings, Inc. | 95.21 Million USD | -765.769% |
| Alzamend Neuro, Inc. | 631.58 Thousand USD | -130414.829% |
| Rocket Pharmaceuticals, Inc. | 566.34 Million USD | -45.551% |
| Aptose Biosciences Inc. | 12.92 Million USD | -6278.899% |
| ZyVersa Therapeutics, Inc. | 22.11 Million USD | -3627.527% |
| Soligenix, Inc. | 9.79 Million USD | -8313.683% |
| Century Therapeutics, Inc. | 360.69 Million USD | -128.538% |
| Kura Oncology, Inc. | 448.93 Million USD | -83.616% |
| TScan Therapeutics, Inc. | 272.14 Million USD | -202.891% |
| Intensity Therapeutics, Inc. | 17.29 Million USD | -4666.21% |
| Ocean Biomedical, Inc. | 110.91 Million USD | -643.221% |
| CytomX Therapeutics, Inc. | 205.15 Million USD | -301.809% |
| Autolus Therapeutics plc | 375.38 Million USD | -119.594% |
| Mineralys Therapeutics, Inc. | 251.63 Million USD | -227.583% |
| EyePoint Pharmaceuticals, Inc. | 355.18 Million USD | -132.081% |
| Eterna Therapeutics Inc. | 49.13 Million USD | -1577.758% |
| Adaptive Biotechnologies Corporation | 661.13 Million USD | -24.682% |
| GRI Bio, Inc. | 2.95 Million USD | -27786.198% |
| Xenetic Biosciences, Inc. | 10.6 Million USD | -7672.734% |
| Tenaya Therapeutics, Inc. | 170.51 Million USD | -383.427% |
| IGM Biosciences, Inc. | 423.41 Million USD | -94.685% |
| INmune Bio, Inc. | 57 Million USD | -1346.143% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -270.469% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -882.015% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -3056.26% |
| Entero Therapeutics, Inc. | 6.88 Million USD | -11875.776% |
| Milestone Pharmaceuticals Inc. | 75.22 Million USD | -995.786% |
| X4 Pharmaceuticals, Inc. | 147.25 Million USD | -459.777% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -398.064% |
| Coherus BioSciences, Inc. | 629.6 Million USD | -30.926% |
| Verastem, Inc. | 149.71 Million USD | -450.579% |
| Abeona Therapeutics Inc. | 64 Million USD | -1187.954% |
| Pliant Therapeutics, Inc. | 512.15 Million USD | -60.951% |
| Tonix Pharmaceuticals Holding Corp. | 154.45 Million USD | -433.686% |
| Histogen Inc. | 19.07 Million USD | -4221.9% |
| Aprea Therapeutics, Inc. | 22.65 Million USD | -3539.336% |
| Surrozen, Inc. | 46.08 Million USD | -1688.88% |
| Organovo Holdings, Inc. | 6.34 Million USD | -12883.399% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -19031.787% |
| Ovid Therapeutics Inc. | 144.02 Million USD | -472.335% |
| Panbela Therapeutics, Inc. | 11.8 Million USD | -6884.545% |
| CASI Pharmaceuticals, Inc. | 75.26 Million USD | -995.175% |
| Cadrenal Therapeutics, Inc. Common Stock | 8.51 Million USD | -9575.922% |
| Centessa Pharmaceuticals plc | 362.96 Million USD | -127.104% |
| Hepion Pharmaceuticals, Inc. | 18.09 Million USD | -4455.642% |
| Arcturus Therapeutics Holdings Inc. | 429.4 Million USD | -91.968% |
| BioRestorative Therapies, Inc. | 12.61 Million USD | -6436.111% |
| Apollomics, Inc. | 55.38 Million USD | -1388.284% |
| Amarin Corporation plc | 831.68 Million USD | 0.886% |
| Mesoblast Limited | 669.15 Million USD | -23.188% |
| Turnstone Biologics Corp. | 112.81 Million USD | -630.679% |
| Kymera Therapeutics, Inc. | 575.75 Million USD | -43.17% |
| Synaptogenix, Inc. | 31.11 Million USD | -2549.369% |
| Tiziana Life Sciences Ltd | 12.18 Million USD | -6665.561% |
| Aurinia Pharmaceuticals Inc. | 548.06 Million USD | -50.406% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -13937.455% |
| Monopar Therapeutics Inc. | 7.34 Million USD | -11122.575% |
| Exelixis, Inc. | 2.94 Billion USD | 71.985% |
| Better Therapeutics, Inc. | 22.94 Million USD | -3492.887% |
| Nurix Therapeutics, Inc. | 364.53 Million USD | -126.126% |
| Apellis Pharmaceuticals, Inc. | 788.73 Million USD | -4.512% |
| NLS Pharmaceutics AG | 1.84 Million USD | -44538.671% |
| Dermata Therapeutics, Inc. | 7.97 Million USD | -10231.543% |
| Aridis Pharmaceuticals, Inc. | 14.69 Million USD | -5509.5% |
| Gritstone bio, Inc. | 177.76 Million USD | -363.701% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -764.244% |
| TNF Pharmaceuticals, Inc. | 17.86 Million USD | -4514.845% |
| Avid Bioservices, Inc. | 336.55 Million USD | -144.926% |
| Insmed Incorporated | 1.32 Billion USD | 38.014% |
| Virpax Pharmaceuticals, Inc. | 9.62 Million USD | -8461.347% |
| MediWound Ltd. | 66.45 Million USD | -1140.338% |
| OmniAb, Inc. | 401.98 Million USD | -105.061% |
| Alector, Inc. | 621.82 Million USD | -32.564% |
| Seres Therapeutics, Inc. | 358.6 Million USD | -129.871% |
| Checkpoint Therapeutics, Inc. | 5.37 Million USD | -15227.557% |
| Viracta Therapeutics, Inc. | 56.69 Million USD | -1354.025% |
| Zai Lab Limited | 1.03 Billion USD | 20.455% |
| Revance Therapeutics, Inc. | 478.45 Million USD | -72.287% |
| Aura Biosciences, Inc. | 255.07 Million USD | -223.166% |
| Lyell Immunopharma, Inc. | 750.02 Million USD | -9.905% |
| Immunic, Inc. | 54.29 Million USD | -1418.105% |
| Tarsus Pharmaceuticals, Inc. | 266.22 Million USD | -209.632% |
| Veracyte, Inc. | 1.13 Billion USD | 27.553% |
| InMed Pharmaceuticals Inc. | 11.82 Million USD | -6872.268% |
| FibroGen, Inc. | 423.52 Million USD | -94.63% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -23364.731% |
| Adial Pharmaceuticals, Inc. | 4.73 Million USD | -17303.098% |
| Sonnet BioTherapeutics Holdings, Inc. | 5.42 Million USD | -15082.233% |
| Jazz Pharmaceuticals plc | 11.39 Billion USD | 92.765% |
| Cyclacel Pharmaceuticals, Inc. | 8.8 Million USD | -9261.908% |
| Amylyx Pharmaceuticals, Inc. | 517.45 Million USD | -59.302% |
| TG Therapeutics, Inc. | 329.58 Million USD | -150.106% |
| Galecto, Inc. | 38.22 Million USD | -2056.371% |
| Calithera Biosciences, Inc. | 28.67 Million USD | -2774.585% |
| Fortrea Holdings Inc. | 4.35 Billion USD | 81.082% |
| KalVista Pharmaceuticals, Inc. | 235.4 Million USD | -250.171% |
| Aptevo Therapeutics Inc. | 24.84 Million USD | -3218.235% |
| XBiotech Inc. | 227.24 Million USD | -262.746% |
| Jasper Therapeutics, Inc. | 95.38 Million USD | -764.244% |
| Lyra Therapeutics, Inc. | 142.6 Million USD | -478.062% |
| Foghorn Therapeutics Inc. | 285.91 Million USD | -188.307% |
| Y-mAbs Therapeutics, Inc. | 127.86 Million USD | -544.657% |
| Theravance Biopharma, Inc. | 381.99 Million USD | -115.79% |
| Ultragenyx Pharmaceutical Inc. | 1.49 Billion USD | 44.714% |
| Metagenomi, Inc. Common Stock | 364.84 Million USD | -125.938% |
| Vaxxinity, Inc. | 44.35 Million USD | -1758.535% |
| BioCryst Pharmaceuticals, Inc. | 516.96 Million USD | -59.455% |
| Gain Therapeutics, Inc. | 18.6 Million USD | -4329.584% |
| Cartesian Therapeutics, Inc. | 305.05 Million USD | -170.223% |
| NexImmune, Inc. | 8.59 Million USD | -9491.819% |
| Creative Medical Technology Holdings, Inc. | 10.71 Million USD | -7592.967% |
| Marker Therapeutics, Inc. | 17.12 Million USD | -4712.852% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 97.508% |
| Chemomab Therapeutics Ltd. | 22.15 Million USD | -3621.327% |
| Scopus BioPharma Inc. | 392.26 Thousand USD | -210042.633% |
| RAPT Therapeutics, Inc. | 173.32 Million USD | -375.579% |
| Ainos, Inc. | 31.84 Million USD | -2488.785% |
| Pluri Inc. | 39.52 Million USD | -1985.45% |
| Prothena Corporation plc | 696.38 Million USD | -18.371% |
| Adaptimmune Therapeutics plc | 282.61 Million USD | -191.674% |
| Celularity Inc. | 143.88 Million USD | -472.883% |
| Rallybio Corporation | 115.62 Million USD | -612.953% |
| Cue Biopharma, Inc. | 61.53 Million USD | -1239.698% |
| MeiraGTx Holdings plc | 458.16 Million USD | -79.916% |
| Omeros Corporation | 378.26 Million USD | -117.918% |
| Humacyte, Inc. | 128.22 Million USD | -542.877% |
| Immunocore Holdings plc | 597 Million USD | -38.076% |
| Cocrystal Pharma, Inc. | 31.25 Million USD | -2537.052% |
| Cidara Therapeutics, Inc. | 68.53 Million USD | -1102.854% |
| Blueprint Medicines Corporation | 1.04 Billion USD | 21.438% |
| CalciMedica, Inc. | 12.18 Million USD | -6665.006% |
| Cabaletta Bio, Inc. | 253.65 Million USD | -224.982% |
| Marinus Pharmaceuticals, Inc. | 170.9 Million USD | -382.316% |
| Scholar Rock Holding Corporation | 311.03 Million USD | -165.024% |
| Sana Biotechnology, Inc. | 565.29 Million USD | -45.819% |
| Pulmatrix, Inc. | 33.95 Million USD | -2327.457% |
| Elicio Therapeutics, Inc. | 27.14 Million USD | -2936.602% |
| Vigil Neuroscience, Inc. | 140.85 Million USD | -485.211% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 36.639% |
| Adlai Nortye Ltd. American Depositary Shares | 130.18 Million USD | -533.169% |
| Eloxx Pharmaceuticals, Inc. | 21.12 Million USD | -3802.457% |
| Nutriband Inc. | 7.51 Million USD | -10865.799% |
| Protara Therapeutics, Inc. | 78.95 Million USD | -944.046% |
| Vor Biopharma Inc. | 209.82 Million USD | -292.853% |
| Roivant Sciences Ltd. | 7.22 Billion USD | 88.587% |
| Evogene Ltd. | 51.1 Million USD | -1513.111% |
| ProKidney Corp. | 420.55 Million USD | -96.008% |
| Applied Therapeutics, Inc. | 54.83 Million USD | -1403.321% |
| Hoth Therapeutics, Inc. | 9.52 Million USD | -8558.529% |
| BridgeBio Pharma, Inc. | 546.38 Million USD | -50.869% |
| CorMedix Inc. | 82.05 Million USD | -904.529% |
| BioLineRx Ltd. | 63.92 Million USD | -1189.505% |
| Tango Therapeutics, Inc. | 402.56 Million USD | -104.765% |
| Galectin Therapeutics Inc. | 28.2 Million USD | -2823.106% |
| Atai Life Sciences N.V. | 293.47 Million USD | -180.878% |
| Renovaro Biosciences Inc. | 163.12 Million USD | -405.314% |
| Aerovate Therapeutics, Inc. | 127.41 Million USD | -546.938% |
| Zentalis Pharmaceuticals, Inc. | 562.02 Million USD | -46.668% |
| Sagimet Biosciences Inc. | 96.71 Million USD | -752.279% |
| MediciNova, Inc. | 66.26 Million USD | -1143.875% |
| Praxis Precision Medicines, Inc. | 87.94 Million USD | -837.277% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -18372.626% |
| GeoVax Labs, Inc. | 9.28 Million USD | -8779.635% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -40.134% |
| Biomea Fusion, Inc. | 199.92 Million USD | -312.308% |
| PTC Therapeutics, Inc. | 1.9 Billion USD | 56.687% |
| Mereo BioPharma Group plc | 66.49 Million USD | -1139.592% |
| Cullinan Oncology, Inc. | 485.09 Million USD | -69.928% |
| Syndax Pharmaceuticals, Inc. | 612.88 Million USD | -34.499% |
| Absci Corporation | 234.48 Million USD | -251.551% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -11168.845% |
| 4D Molecular Therapeutics, Inc. | 339.89 Million USD | -142.524% |
| Dyne Therapeutics, Inc. | 165.08 Million USD | -399.337% |
| Kiniksa Pharmaceuticals, Ltd. | 526.32 Million USD | -56.618% |
| Ventyx Biosciences, Inc. | 277.69 Million USD | -196.844% |
| Allakos Inc. | 243.61 Million USD | -238.375% |
| Imunon, Inc. | 21.91 Million USD | -3660.897% |
| Fulcrum Therapeutics, Inc. | 257.69 Million USD | -219.882% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -32.63% |
| BioAtla, Inc. | 119.65 Million USD | -588.893% |
| NLS Pharmaceutics AG | 1.84 Million USD | -44538.671% |
| Bio-Path Holdings, Inc. | 3.22 Million USD | -25499.876% |
| Allogene Therapeutics, Inc. | 642.83 Million USD | -28.231% |
| Larimar Therapeutics, Inc. | 95.93 Million USD | -759.244% |
| XOMA Corporation | 234.3 Million USD | -251.819% |
| Kezar Life Sciences, Inc. | 221.23 Million USD | -272.597% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -555.03% |
| aTyr Pharma, Inc. | 122.06 Million USD | -575.298% |
| Aligos Therapeutics, Inc. | 153.9 Million USD | -435.607% |
| Akero Therapeutics, Inc. | 580.27 Million USD | -42.057% |
| Viridian Therapeutics, Inc. | 490.42 Million USD | -68.082% |
| Eliem Therapeutics, Inc. | 110.46 Million USD | -646.197% |
| EyeGate Pharmaceuticals, Inc. | 15.15 Million USD | -5338.316% |
| Akari Therapeutics, Plc | 4.35 Million USD | -18828.037% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4738.292% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 52.442% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -26628.915% |
| UroGen Pharma Ltd. | 178.31 Million USD | -362.291% |
| Sutro Biopharma, Inc. | 470.73 Million USD | -75.112% |
| ZIVO Bioscience, Inc. | 555.71 Thousand USD | -148234.308% |
| Orgenesis Inc. | 14.55 Million USD | -5564.623% |
| Entera Bio Ltd. | 11.76 Million USD | -6906.511% |
| GH Research PLC | 226.3 Million USD | -264.258% |
| Lisata Therapeutics, Inc. | 54.69 Million USD | -1407.142% |
| Reneo Pharmaceuticals, Inc. | 107.43 Million USD | -667.262% |
| Xencor, Inc. | 952.69 Million USD | 13.475% |
| 60 Degrees Pharmaceuticals, Inc. | 7.78 Million USD | -10490.188% |
| Replimune Group, Inc. | 487.72 Million USD | -69.013% |
| Coeptis Therapeutics Holdings, Inc. | 8.07 Million USD | -10113.194% |
| Vanda Pharmaceuticals Inc. | 648.44 Million USD | -27.123% |
| Lexaria Bioscience Corp. | 3.08 Million USD | -26628.915% |
| Portage Biotech Inc. | 7.77 Million USD | -10496.683% |
| Cardio Diagnostics Holdings, Inc. | 4.46 Million USD | -18372.626% |
| Olema Pharmaceuticals, Inc. | 276.94 Million USD | -197.646% |
| OncoCyte Corporation | 74.89 Million USD | -1000.673% |
| Qualigen Therapeutics, Inc. | 2.03 Million USD | -40441.833% |
| Processa Pharmaceuticals, Inc. | 5.78 Million USD | -14145.15% |
| Purple Biotech Ltd. | 44.3 Million USD | -1760.674% |
| CollPlant Biotechnologies Ltd. | 34.12 Million USD | -2315.507% |
| scPharmaceuticals Inc. | 94.47 Million USD | -772.486% |
| ProMIS Neurosciences, Inc. | 18.04 Million USD | -4468.124% |
| HilleVax, Inc. | 344.43 Million USD | -139.325% |
| NeuroSense Therapeutics Ltd. | 3.17 Million USD | -25854.534% |
| Tharimmune, Inc. | 10.94 Million USD | -7430.481% |
| Genprex, Inc. | 10.67 Million USD | -7625.12% |
| Neumora Therapeutics, Inc. Common Stock | 496.19 Million USD | -66.127% |
| Atossa Therapeutics, Inc. | 96.25 Million USD | -756.414% |
| XTL Biopharmaceuticals Ltd. | 2.42 Million USD | -33878.401% |
| Virios Therapeutics, Inc. | 4.16 Million USD | -19689.405% |
| OKYO Pharma Limited | 1.54 Million USD | -53383.115% |
| Savara Inc. | 177.56 Million USD | -364.236% |
| Curis, Inc. | 77.28 Million USD | -966.634% |
| Daré Bioscience, Inc. | 21.28 Million USD | -3773.262% |
| Carmell Therapeutics Corporation | 63.94 Million USD | -1189.025% |
| Titan Pharmaceuticals, Inc. | 8.08 Million USD | -10094.361% |
| Achieve Life Sciences, Inc. | 19.37 Million USD | -4155.413% |
| BeiGene, Ltd. | 5.8 Billion USD | 85.801% |
| Kiromic BioPharma, Inc. | 12.16 Million USD | -6673.901% |
| Revolution Medicines, Inc. Warrant | 2.08 Billion USD | 60.532% |
| Protagonist Therapeutics, Inc. | 357.95 Million USD | -130.287% |
| Erasca, Inc. | 395.29 Million USD | -108.531% |
| bluebird bio, Inc. | 619.16 Million USD | -33.134% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -18966.52% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 87.951% |
| DBV Technologies S.A. | 182.98 Million USD | -350.48% |
| Protagenic Therapeutics, Inc. | 4.32 Million USD | -18966.52% |
| Moderna, Inc. | 18.42 Billion USD | 95.526% |
| Vincerx Pharma, Inc. | 18.21 Million USD | -4424.982% |
| Fresh Tracks Therapeutics, Inc. | 11.58 Million USD | -7014.759% |
| Molecular Templates, Inc. | 35.38 Million USD | -2229.695% |
| Acrivon Therapeutics, Inc. Common Stock | 138.26 Million USD | -496.186% |
| Travere Therapeutics, Inc. | 788.91 Million USD | -4.488% |
| Monte Rosa Therapeutics, Inc. | 303.75 Million USD | -171.375% |
| Spruce Biosciences, Inc. | 103.94 Million USD | -693.023% |
| Celldex Therapeutics, Inc. | 465.62 Million USD | -77.034% |
| Cogent Biosciences, Inc. | 313.43 Million USD | -162.993% |
| MacroGenics, Inc. | 306.82 Million USD | -168.664% |
| RenovoRx, Inc. | 1.46 Million USD | -56128.922% |
| Adicet Bio, Inc. | 207.29 Million USD | -297.654% |
| Prime Medicine, Inc. | 193.85 Million USD | -325.232% |
| Aditxt, Inc. | 44.57 Million USD | -1749.141% |
| Adagene Inc. | 115.72 Million USD | -612.282% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -18406.534% |
| Quantum-Si incorporated | 298.25 Million USD | -176.384% |
| Maravai LifeSciences Holdings, Inc. | 1.48 Billion USD | 44.582% |
| Acurx Pharmaceuticals, Inc. | 7.7 Million USD | -10592.734% |
| Voyager Therapeutics, Inc. | 351.28 Million USD | -134.66% |
| SciSparc Ltd. | 11.18 Million USD | -7271.812% |
| Vericel Corporation | 353.65 Million USD | -133.083% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6649.713% |
| Minerva Neurosciences, Inc. | 56.9 Million USD | -1348.694% |
| Generation Bio Co. | 374.75 Million USD | -119.96% |
| Astria Therapeutics, Inc. | 254.66 Million USD | -223.685% |
| Black Diamond Therapeutics, Inc. | 158.56 Million USD | -419.853% |
| Arcutis Biotherapeutics, Inc. | 341.36 Million USD | -141.476% |
| Invivyd, Inc. | 229.18 Million USD | -259.679% |
| Relay Therapeutics, Inc. | 843.98 Million USD | 2.33% |
| Quoin Pharmaceuticals, Ltd. | 12.16 Million USD | -6673.733% |
| Spero Therapeutics, Inc. | 182.39 Million USD | -351.952% |
| Artelo Biosciences, Inc. | 20.42 Million USD | -3936.016% |
| 2seventy bio, Inc. | 565.42 Million USD | -45.787% |
| ADMA Biologics, Inc. | 329.18 Million USD | -150.413% |
| Clene Inc. | 52.34 Million USD | -1474.895% |
| Capricor Therapeutics, Inc. | 58.73 Million USD | -1303.465% |
| Boundless Bio, Inc. Common Stock | 129.89 Million USD | -534.607% |
| GeoVax Labs, Inc. | 9.28 Million USD | -8779.635% |
| Recursion Pharmaceuticals, Inc. | 653.69 Million USD | -26.1% |
| Citius Pharmaceuticals, Inc. | 103.61 Million USD | -695.586% |
| Contineum Therapeutics, Inc. Class A Common Stock | 130.38 Million USD | -532.212% |
| Relmada Therapeutics, Inc. | 97.55 Million USD | -745.001% |
| Finch Therapeutics Group, Inc. | 70.99 Million USD | -1061.058% |
| ALX Oncology Holdings Inc. | 242.55 Million USD | -239.85% |
| Vir Biotechnology, Inc. | 1.96 Billion USD | 57.945% |
| Evaxion Biotech A/S | 12.88 Million USD | -6295.689% |
| Ocular Therapeutix, Inc. | 252.06 Million USD | -227.032% |
| Verve Therapeutics, Inc. | 752.68 Million USD | -9.516% |
| Trevena, Inc. | 40.6 Million USD | -1930.085% |
| Surrozen, Inc. | 46.08 Million USD | -1688.88% |
| Tyra Biosciences, Inc. | 225.85 Million USD | -264.973% |
| Cingulate Inc. | 3.49 Million USD | -23509.655% |
| Galmed Pharmaceuticals Ltd. | 16.62 Million USD | -4857.099% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1154.858% |
| Tenax Therapeutics, Inc. | 11.68 Million USD | -6954.705% |
| Terns Pharmaceuticals, Inc. | 268.51 Million USD | -206.988% |
| ACADIA Pharmaceuticals Inc. | 748.95 Million USD | -10.062% |
| Connect Biopharma Holdings Limited | 125.89 Million USD | -554.78% |
| Clearmind Medicine Inc. | 4.32 Million USD | -18962.022% |
| Kronos Bio, Inc. | 213.27 Million USD | -286.497% |
| Bolt Biotherapeutics, Inc. | 159.78 Million USD | -415.894% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -9529.174% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -123.701% |
| Statera Biopharma, Inc. | 21.16 Million USD | -3793.851% |
| ImmunityBio, Inc. | 504.45 Million USD | -63.408% |
| Korro Bio, Inc. | 221.66 Million USD | -271.878% |
| Kineta, Inc. | 10.28 Million USD | -7917.858% |
| BioVie Inc. | 25.2 Million USD | -3170.012% |
| Codexis, Inc. | 136.56 Million USD | -503.625% |
| Celularity Inc. | 143.88 Million USD | -472.883% |
| Crinetics Pharmaceuticals, Inc. | 635.35 Million USD | -29.741% |
| Celcuity Inc. | 191.21 Million USD | -331.084% |
| Virax Biolabs Group Limited | 5.48 Million USD | -14931.376% |
| Cibus, Inc. | 544.41 Million USD | -51.414% |
| Eledon Pharmaceuticals, Inc. | 125.89 Million USD | -554.77% |
| eFFECTOR Therapeutics, Inc. | 20.54 Million USD | -3912.442% |
| IN8bio, Inc. | 33.7 Million USD | -2345.388% |
| Kodiak Sciences Inc. | 479.37 Million USD | -71.957% |
| Annexon, Inc. | 297.67 Million USD | -176.919% |
| Adverum Biotechnologies, Inc. | 173.01 Million USD | -376.456% |
| Assembly Biosciences, Inc. | 137.46 Million USD | -499.638% |
| Avalo Therapeutics, Inc. | 20.99 Million USD | -3826.623% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 72.432% |
| Eyenovia, Inc. | 28.77 Million USD | -2764.26% |
| Puma Biotechnology, Inc. | 230.52 Million USD | -257.577% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -11310.797% |
| Xilio Therapeutics, Inc. | 60.92 Million USD | -1252.979% |
| Arcellx, Inc. | 825.13 Million USD | 0.099% |
| Cardiff Oncology, Inc. | 81.63 Million USD | -909.733% |
| Enanta Pharmaceuticals, Inc. | 462.27 Million USD | -78.317% |
| Regulus Therapeutics Inc. | 30.75 Million USD | -2580.702% |
| Moolec Science SA | 24.05 Million USD | -3327.326% |
| Acumen Pharmaceuticals, Inc. | 310.12 Million USD | -165.801% |
| Geron Corporation | 394.07 Million USD | -109.177% |
| LAVA Therapeutics N.V. | 101.71 Million USD | -710.457% |
| Royalty Pharma plc | 16.38 Billion USD | 94.968% |
| Atea Pharmaceuticals, Inc. | 594.96 Million USD | -38.548% |
| Greenwich LifeSciences, Inc. | 6.99 Million USD | -11684.672% |
| TFF Pharmaceuticals, Inc. | 12.02 Million USD | -6753.699% |
| Mersana Therapeutics, Inc. | 226.06 Million USD | -264.645% |
| Humacyte, Inc. | 128.22 Million USD | -542.877% |
| Structure Therapeutics Inc. | 482.01 Million USD | -71.014% |
| 89bio, Inc. | 596.26 Million USD | -38.246% |
| PMV Pharmaceuticals, Inc. | 252.15 Million USD | -226.912% |
| Avenue Therapeutics, Inc. | 1.85 Million USD | -44457.622% |
| Genelux Corporation | 27.89 Million USD | -2855.279% |
| Trevi Therapeutics, Inc. | 89.4 Million USD | -822.023% |
| Lexicon Pharmaceuticals, Inc. | 229.42 Million USD | -259.29% |
| Notable Labs, Ltd. | 19.54 Million USD | -4118.392% |
| Liquidia Corporation | 120.43 Million USD | -584.472% |
| Mustang Bio, Inc. | 17.74 Million USD | -4546.128% |
| Immunovant, Inc. | 666.71 Million USD | -23.639% |
| Quantum-Si incorporated | 298.25 Million USD | -176.384% |
| Arbutus Biopharma Corporation | 144.4 Million USD | -470.852% |
| DiaMedica Therapeutics Inc. | 54.16 Million USD | -1422.001% |
| Vera Therapeutics, Inc. | 175.54 Million USD | -369.573% |
| Acasti Pharma Inc. | 73.3 Million USD | -1024.578% |
| MiNK Therapeutics, Inc. | 4.55 Million USD | -18007.757% |
| Pasithea Therapeutics Corp. | 26.11 Million USD | -3056.26% |
| Xenon Pharmaceuticals Inc. | 964.79 Million USD | 14.561% |
| Elevai Labs, Inc. Common Stock | 5.18 Million USD | -15783.026% |
| NeuroBo Pharmaceuticals, Inc. | 22.78 Million USD | -3518.436% |
| Tempest Therapeutics, Inc. | 51.6 Million USD | -1497.419% |
| Soleno Therapeutics, Inc. | 180.69 Million USD | -356.202% |
| PepGen Inc. | 143.05 Million USD | -476.235% |
| Moleculin Biotech, Inc. | 38.21 Million USD | -2056.935% |
| United Therapeutics Corporation | 7.16 Billion USD | 88.498% |
| Nuvectis Pharma, Inc. | 19.18 Million USD | -4196.669% |
| Solid Biosciences Inc. | 164.93 Million USD | -399.77% |
| BriaCell Therapeutics Corp. | 5.87 Million USD | -13937.455% |
| Immuneering Corporation | 102.58 Million USD | -703.548% |
| Lixte Biotechnology Holdings, Inc. | 4.3 Million USD | -19031.787% |
| Silo Pharma, Inc. | 7.74 Million USD | -10541.634% |
| Belite Bio, Inc | 94.64 Million USD | -770.983% |
| XOMA Corporation | 234.3 Million USD | -251.819% |
| ARS Pharmaceuticals, Inc. | 233.18 Million USD | -253.498% |
| Bionomics Limited | 27.64 Million USD | -2881.349% |
| Apogee Therapeutics, Inc. | 401.4 Million USD | -105.358% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -667.605% |
| uniQure N.V. | 831.68 Million USD | 0.887% |
| Cassava Sciences, Inc. | 151.66 Million USD | -443.518% |
| Estrella Immunopharma, Inc. | 4.45 Million USD | -18406.534% |
| Poseida Therapeutics, Inc. | 273.88 Million USD | -200.972% |
| Forte Biosciences, Inc. | 38.98 Million USD | -2014.715% |
| Anebulo Pharmaceuticals, Inc. | 4.07 Million USD | -20137.98% |
| Enlivex Therapeutics Ltd. | 36.83 Million USD | -2138.104% |
| Conduit Pharmaceuticals Inc. | 7.22 Million USD | -11310.797% |
| SeaStar Medical Holding Corporation | 3.51 Million USD | -23364.731% |
| FibroBiologics, Inc. Common Stock | 11.82 Million USD | -6873.319% |
| Altimmune, Inc. | 210.64 Million USD | -291.339% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -5.97% |
| Alpha Tau Medical Ltd. | 107.38 Million USD | -667.605% |
| Compugen Ltd. | 121.33 Million USD | -579.378% |
| Peak Bio, Inc. | 2.59 Million USD | -31648.237% |
| Zevra Therapeutics, Inc. | 172.32 Million USD | -378.344% |
| Benitec Biopharma Inc. | 52.21 Million USD | -1478.847% |
| Spyre Therapeutics, Inc. | 341.85 Million USD | -141.127% |
| NKGen Biotech, Inc. Common Stock | 34.77 Million USD | -2270.563% |
| Zura Bio Limited | 100.84 Million USD | -717.425% |
| PolyPid Ltd. | 15.37 Million USD | -5262.451% |
| Aileron Therapeutics, Inc. | 119.28 Million USD | -591.042% |
| NKGen Biotech, Inc. Warrants | 34.77 Million USD | -2270.563% |
| Instil Bio, Inc. | 325.63 Million USD | -153.145% |
| argenx SE | 4.54 Billion USD | 81.853% |
| Immunome, Inc. | 148.54 Million USD | -454.945% |
| Compass Therapeutics, Inc. | 156.87 Million USD | -425.46% |
| Verona Pharma plc | 308.12 Million USD | -167.527% |
| enGene Holdings Inc. Warrants | 86.95 Million USD | -847.936% |
| Shattuck Labs, Inc. | 159.56 Million USD | -416.605% |
| CervoMed Inc. | 9.97 Million USD | -8165.874% |
| LENZ Therapeutics, Inc. | 188.45 Million USD | -337.405% |
| Plus Therapeutics, Inc. | 11.38 Million USD | -7138.462% |
| Dianthus Therapeutics, Inc. | 179.4 Million USD | -359.472% |
| Moolec Science SA | 24.05 Million USD | -3327.326% |
| Enveric Biosciences, Inc. | 6.11 Million USD | -13374.764% |
| Inovio Pharmaceuticals, Inc. | 172.94 Million USD | -376.636% |
| AnaptysBio, Inc. | 452.38 Million USD | -82.214% |
| Design Therapeutics, Inc. | 289.64 Million USD | -184.597% |
| Leap Therapeutics, Inc. | 72.82 Million USD | -1031.913% |
| NeurAxis, Inc. | 509.49 Thousand USD | -161689.84% |
| Seelos Therapeutics, Inc. | 5.41 Million USD | -15114.396% |
| Lumos Pharma, Inc. | 40.63 Million USD | -1928.436% |
| Achilles Therapeutics plc | 161.45 Million USD | -410.551% |
| enGene Holdings Inc. Common Stock | 86.95 Million USD | -847.936% |
| 180 Life Sciences Corp. | 5.25 Million USD | -15572.968% |
| Opiant Pharmaceuticals, Inc. | 70.42 Million USD | -1070.441% |
| CERo Therapeutics Holdings, Inc. | 8.56 Million USD | -9529.174% |
| Nutriband Inc. | 7.51 Million USD | -10865.799% |
| ORIC Pharmaceuticals, Inc. | 254.68 Million USD | -223.66% |
| CG Oncology, Inc. Common stock | 199.3 Million USD | -313.604% |
| Fractyl Health, Inc. Common Stock | 76.21 Million USD | -981.609% |
| Rani Therapeutics Holdings, Inc. | 57.91 Million USD | -1323.296% |
| MoonLake Immunotherapeutics | 526.54 Million USD | -56.553% |
| Palisade Bio, Inc. | 14.05 Million USD | -5766.183% |
| Tourmaline Bio, Inc. | 210.29 Million USD | -291.981% |
| Beam Therapeutics Inc. | 1.45 Billion USD | 43.529% |
| Neurogene Inc. | 222.57 Million USD | -270.358% |
| Mirum Pharmaceuticals, Inc. | 646.62 Million USD | -27.481% |
| AEON Biopharma, Inc. | 6.84 Million USD | -11942.6% |
| CARGO Therapeutics, Inc. Common Stock | 453.03 Million USD | -81.954% |
| Sesen Bio, Inc. | 189.17 Million USD | -335.745% |
| Enliven Therapeutics, Inc. | 271.86 Million USD | -203.206% |
| Kiora Pharmaceuticals, Inc. | 13.71 Million USD | -5911.696% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -5.634% |
| Taysha Gene Therapies, Inc. | 266.99 Million USD | -208.74% |
| Athira Pharma, Inc. | 160.24 Million USD | -414.41% |
| Vaccinex, Inc. | 3.63 Million USD | -22602.176% |
| HCW Biologics Inc. | 28.51 Million USD | -2790.951% |
| XOMA Corporation | 234.3 Million USD | -251.819% |
| Nektar Therapeutics | 398.03 Million USD | -107.097% |
| Arvinas, Inc. | 1.3 Billion USD | 36.815% |
| Tevogen Bio Holdings Inc. | 17.03 Million USD | -4738.292% |
| Merus N.V. | 458.49 Million USD | -79.788% |
| Omega Therapeutics, Inc. | 204.36 Million USD | -303.353% |
| Quince Therapeutics, Inc. | 180.2 Million USD | -357.435% |
| Rezolute, Inc. | 132.73 Million USD | -521.014% |
| Clene Inc. | 52.34 Million USD | -1474.895% |
| Indaptus Therapeutics, Inc. | 14.92 Million USD | -5423.471% |
| BeyondSpring Inc. | 24.8 Million USD | -3222.783% |
| Synlogic, Inc. | 75.55 Million USD | -991.087% |
| Allarity Therapeutics, Inc. | 11.86 Million USD | -6849.216% |
| Phio Pharmaceuticals Corp. | 9.36 Million USD | -8703.033% |
| Peak Bio, Inc. | 2.59 Million USD | -31648.237% |
| Werewolf Therapeutics, Inc. | 174.83 Million USD | -371.488% |
| Krystal Biotech, Inc. | 818.35 Million USD | -0.728% |
| Karyopharm Therapeutics Inc. | 240.43 Million USD | -242.839% |
| SpringWorks Therapeutics, Inc. | 725.78 Million USD | -13.575% |
| Lipella Pharmaceuticals Inc. | 3.57 Million USD | -22943.777% |
| MannKind Corporation | 475.19 Million USD | -73.468% |
| Ikena Oncology, Inc. | 192.09 Million USD | -329.126% |
| Cyclerion Therapeutics, Inc. | 13.37 Million USD | -6063.571% |
| Gyre Therapeutics, Inc. | 116.53 Million USD | -607.331% |
| Gossamer Bio, Inc. | 311.91 Million USD | -164.275% |
| CohBar, Inc. | 16.36 Million USD | -4936.862% |
| Cognition Therapeutics, Inc. | 35.16 Million USD | -2244.271% |
| NRx Pharmaceuticals, Inc. | 7.31 Million USD | -11168.845% |
| Legend Biotech Corporation | 1.84 Billion USD | 55.409% |
| Mural Oncology plc | 301.74 Million USD | -173.183% |
| Biora Therapeutics, Inc. | 31.21 Million USD | -2540.769% |
| PaxMedica, Inc. Common Stock | 5.68 Million USD | -14411.571% |
| Disc Medicine, Inc. | 367.99 Million USD | -124.001% |
| Champions Oncology, Inc. | 26.13 Million USD | -3054.431% |
| REGENXBIO Inc. | 573.97 Million USD | -43.617% |
| Ensysce Biosciences, Inc. | 2.7 Million USD | -30339.074% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -433.932% |
| Cellectar Biosciences, Inc. | 12.07 Million USD | -6726.306% |
| Edgewise Therapeutics, Inc. | 340.03 Million USD | -142.421% |
| Vaxart, Inc. | 91.83 Million USD | -797.654% |
| PharmaCyte Biotech, Inc. | 59.9 Million USD | -1276.064% |
| Aldeyra Therapeutics, Inc. | 148.32 Million USD | -455.743% |
| Cellectis S.A. | 334.27 Million USD | -146.602% |
| Longeveron Inc. | 12.17 Million USD | -6668.895% |
| Repare Therapeutics Inc. | 253.9 Million USD | -224.66% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 74.75% |
| Inozyme Pharma, Inc. | 200.84 Million USD | -310.42% |
| Revolution Medicines, Inc. | 2.08 Billion USD | 60.532% |
| Nymox Pharmaceutical Corporation | 1.62 Million USD | -50627.138% |
| Third Harmonic Bio, Inc. | 277.71 Million USD | -196.825% |
| ArriVent BioPharma, Inc. Common Stock | 163.09 Million USD | -405.411% |
| AN2 Therapeutics, Inc. | 138.74 Million USD | -494.127% |
| Anixa Biosciences, Inc. | 25.52 Million USD | -3129.825% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 96.373% |
| Denali Therapeutics Inc. | 1.15 Billion USD | 28.564% |
| Revelation Biosciences, Inc. | 12.21 Million USD | -6649.713% |
| Veru Inc. | 50.59 Million USD | -1529.214% |
| Corvus Pharmaceuticals, Inc. | 45.55 Million USD | -1709.576% |
| Cingulate Inc. | 3.49 Million USD | -23509.655% |
| Passage Bio, Inc. | 150.54 Million USD | -447.555% |
| Context Therapeutics Inc. | 16.06 Million USD | -5031.853% |
| Exicure, Inc. | 11.58 Million USD | -7018.446% |
| Day One Biopharmaceuticals, Inc. | 376.04 Million USD | -119.205% |
| Oramed Pharmaceuticals Inc. | 161.64 Million USD | -409.964% |
| Scinai Immunotherapeutics Ltd. | 17.47 Million USD | -4617.926% |
| Rhythm Pharmaceuticals, Inc. | 332.74 Million USD | -147.732% |
| Nuvalent, Inc. | 732.38 Million USD | -12.552% |
| ABVC BioPharma, Inc. | 14.94 Million USD | -5416.004% |
| Carisma Therapeutics, Inc. | 89.55 Million USD | -820.468% |
| Unicycive Therapeutics, Inc. | 14.19 Million USD | -5708.724% |
| OmniAb, Inc. | 401.98 Million USD | -105.061% |
| Anew Medical, Inc. | 19.45 Million USD | -4136.832% |
| Fennec Pharmaceuticals Inc. | 26.72 Million USD | -2984.258% |
| Lipocine Inc. | 23 Million USD | -3483.816% |
| Lexeo Therapeutics, Inc. Common Stock | 139.8 Million USD | -489.61% |
| Nautilus Biotechnology, Inc. | 305.56 Million USD | -169.768% |
| SAB Biotherapeutics, Inc. | 83.94 Million USD | -882.015% |
| G1 Therapeutics, Inc. | 121.54 Million USD | -578.226% |
| Bellerophon Therapeutics, Inc. | 7.93 Million USD | -10288.355% |
| Sage Therapeutics, Inc. | 882.27 Million USD | 6.569% |
| Ocugen, Inc. | 64.54 Million USD | -1177.079% |
| Mind Medicine (MindMed) Inc. | 124.54 Million USD | -561.883% |
| Q32 Bio Inc. | 306.11 Million USD | -169.28% |
| Brainstorm Cell Therapeutics Inc. | 4.2 Million USD | -19489.259% |
| Alumis Inc. Common Stock | 89.61 Million USD | -819.872% |
| Equillium, Inc. | 50.53 Million USD | -1531.34% |
| Kyverna Therapeutics, Inc. | 75.19 Million USD | -996.238% |
| Coya Therapeutics, Inc. | 41.27 Million USD | -1897.203% |
| CNS Pharmaceuticals, Inc. | 1.7 Million USD | -48364.859% |
| Galera Therapeutics, Inc. | 26.14 Million USD | -3053.345% |
| Evelo Biosciences, Inc. | 64.44 Million USD | -1179.179% |
| Comera Life Sciences Holdings, Inc. | 3.72 Million USD | -22016.743% |
| Dominari Holdings Inc. | 57.55 Million USD | -1332.148% |
| Edesa Biotech, Inc. | 8.89 Million USD | -9171.94% |
| vTv Therapeutics Inc. | 11.01 Million USD | -7381.539% |
| Bio-Techne Corporation | 2.81 Billion USD | 70.698% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | 12.037% |
| Harmony Biosciences Holdings, Inc. | 811.44 Million USD | -1.586% |
| Prelude Therapeutics Incorporated | 277.66 Million USD | -196.874% |
| Candel Therapeutics, Inc. | 41.7 Million USD | -1876.682% |
| iTeos Therapeutics, Inc. | 667.58 Million USD | -23.477% |
| Nkarta, Inc. | 378.88 Million USD | -117.564% |
| BioCardia, Inc. | 2.98 Million USD | -27496.786% |
| Iterum Therapeutics plc | 26.25 Million USD | -3039.175% |